Literature DB >> 20004570

P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.

Latha G Nair1, Mousumi Sannigrahi, Stephane Bogen, Patrick Pinto, Kevin X Chen, Andrew Prongay, Xiao Tong, K-C Cheng, Viyyoor Girijavallabhan, F George Njoroge.   

Abstract

SAR studies on the extension of P3 unit of Boceprevir (1, SCH 503034) with amides and lactams and their synthesis is described. Extensive SAR studies resulted in the identification of 36 bearing 4, 4-dimethyl lactam as the new P4 cap unit with improved potency (K(i)( *)=15nM, EC 90=70nM) and pharmacokinetic properties (Rat AUC (PO)=3.52microMh) compared to 1. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004570     DOI: 10.1016/j.bmcl.2009.11.094

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  New developments in the management of hepatitis C virus infection: focus on boceprevir.

Authors:  Marina Berenguer; F Xavier López-Labrador
Journal:  Biologics       Date:  2012-08-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.